Drug Information

Drug (ID: DG00641) and It's Reported Resistant Information

• Name: Topiramate
• Synonyms: Topiramate; 97240-79-4; Topamax; Epitomax; Topamax Sprinkle; Tipiramate; Topiramatum; Topina; McN-4853; Tipiramato; Topiramato; Topimax; Topomax; McN 4853; C12H21NO8S; 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; RWJ-17021-000; RWJ-17021; 2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate; UNII-0H73WJJ391; USL255; USL-255; MFCD00865320; RWJ 17021; [(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate; CHEBI:63631; Tipiramate [French]; Tipiramato [Spanish]; 0H73WJJ391; ((3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-3a-yl)methyl sulfamate; Topiramatum [INN-Latin]; topiramatum [Latin]; Topiramato [INN-Spanish]; Epitoma; Topamac; DSSTox_CID_3688; DSSTox_RID_77148; DSSTox_GSID_23688; ((3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl)methyl sulfamate; [(1R,2S,6S,9R)-4,4,11,11-tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.0^{2,6}]dodecan-6-yl]methyl sulfamate; Topiragen; Topax; Trokendi XR; Qudexy XR; SMR000466325; Topiramate (TPM); TOR; TPM; Topamax (TN); CAS-97240-79-4; BRN 5988957; Sincronil; Qudexy; HSDB 7531; Sulfamate 7; 3hku; 3lxe; USL 255; (-)-topiramate; Topiramate [USAN:USP:INN:BAN]; Topiramate solution; NCGC00095181-01; [(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyl-5,5a,8a,8b-tetrahydrodi[1,3]dioxolo[5,4-b:5',3'-d]pyran-3a-yl]methyl sulfamate; Topiramate- Bio-X; Trokendi xr (TN); KS-1122; Spectrum2_001128; beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate; CBChromo1_000352; BIDD:PXR0127; SCHEMBL34631; BSPBio_002306; Topiramate (JAN/USP/INN); Eprontia (liquid formulation); MLS000759431; MLS001424070; BIDD:GT0854; SPECTRUM1505801; SPBio_000995; CHEMBL220492; GTPL6849; DTXSID8023688; BDBM10887; HMS1922H06; HMS2051L09; HMS2093D20; HMS2232H21; HMS3414C15; HMS3678C15; HMS3715I12; HMS3884C17; Pharmakon1600-01505801; [(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate (non-preferred name); ACT09031; ALBB-022457; HY-B0122; Tox21_111472; Tox21_302401; 2,3:4,5-Bis-O-(1-methylethylidene)-36-D-fructo-pyranose sulfamate; NSC759251; s1438; ZINC95616603; AKOS000424547; Topiramate 1.0 mg/ml in Acetonitrile; Topiramate, >=98% (HPLC), solid; Tox21_111472_1; CCG-100940; CS-1885; DB00273; MCULE-9403222429; NC00190; NSC 759251; NSC-759251; NCGC00178714-01; NCGC00178714-04; NCGC00178714-18; NCGC00255221-01; BT167048; SBI-0206907.P001; SW197570-3; C07502; D00537; F20536; AB00639961-06; AB00639961-08; AB00639961_09; AB00639961_10; 240T794; A900173; Q221174; SR-01000759409; W-60376; Q-201845; SR-01000759409-4; Z1522553470; 2,3:4,5-Di-O-isopropylidene-b-D-fructopyranose sulfamate; Topiramate, United States Pharmacopeia (USP) Reference Standard; 2,3:4,5-Bis-O-(1-methylethylidene)- -D-fructopyranose sulfamate; Topiramate, Pharmaceutical Secondary Standard; Certified Reference Material; Topiramate solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; [(1R,2S,6S,9R)-4,4,11,11-tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.02,6]dodecan-6-yl]methyl sulfamate; [(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyl-5,5a,8a,8b-tetrahydrodi[1,3]dioxolo[4,5-a:5',3'-d]pyran-3a-yl]methyl sulfamate; 2,3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose 1-sulfamate;2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose sulfamate; Topamax; Tracrium; Toiramate:
• Indication:
  In total 4 Indication(s)
  Alcohol dependence [ICD-11: 6C40]; Approved; [1]
  Epilepsy [ICD-11: 8A60]; Approved; [1]
  Epilepsy [ICD-11: 8A60]; Approved; [1]
  Seizure disorder [ICD-11: 8A61-8A6Z]; Approved; [1]
• Target: Glutamate receptor ionotropic kainate 1 (GRIK1); GRIK1_HUMAN; [1]
• Formula: C12H21NO8S
• IsoSMILES: CC1(O[C@@H]2CO[C@@]3([C@H]([C@@H]2O1)OC(O3)(C)C)COS(=O)(=O)N)C
• InChI: 1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1
• InChIKey: KJADKKWYZYXHBB-XBWDGYHZSA-N
• PubChem CID: 5284627
• ChEBI ID: CHEBI:63631
• TTD Drug ID: D07VDZ
• VARIDT ID: DR01372
• INTEDE ID: DR1618
• DrugBank ID: DB00273

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-08: Nervous system diseases

Genetic epileptic syndromes [ICD-11: 8A61]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Potassium inwardly rectifying channel subfamily J member 10 (KCNJ10) [1]

• Molecule Alteration: SNP; rs12402969 C+ Genotypes CC+CT
• Sensitive Disease: Genetic generalized epilepsies [ICD-11: 8A61.0]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: Genotyping assay
• Mechanism Description: By analyzing the association between KCNJ10 polymorphisms and anti-epileptic drug efficacy of GGEs we found the frequency of rs12402969 C allele and CC+CT genotypes were higher in GGEs drug responsive patients than that in drug resistant patients

References

• Ref 1: Common variants of KCNJ10 are associated with susceptibility and anti-epileptic drug resistance in Chinese genetic generalized epilepsies .PLoS One. 2015 Apr 13;10(4):e0124896. doi: 10.1371/journal.pone.0124896. eCollection 2015. 10.1371/journal.pone.0124896